论文部分内容阅读
目的探讨E2F1、MDM2及P53在胃肠道间质瘤(gastrointestinal stromal tumors,GIST)中的表达及与GIST临床病理特征和预后的关系。方法利用组织芯片技术及免疫组化EnVision法检测123例GIST中E2F1、MDM2及P53的表达情况,分析三者表达与临床病理特征的关系,并对三者与GIST预后的关系进行统计学分析。结果 123例GIST中108例有三种蛋白均可评估,108例中E2F1、MDM2及P53蛋白三者阳性表达率分别为62.0%,43.5%和57.4%。三者表达均与NIH分级呈显著正相关(均P<0.001);在不同发生部位、是否坏死及有无转移复发之间差异均有显著性意义(均P<0.05),且三者表达在肠道发生的GIST明显高于胃和肠道外部位(P<0.05),胃和肠道外相比差异无统计学意义(P>0.05);而在不同发生年龄及不同细胞类型间相比差异均无统计学意义(均P>0.05)。结论 E2F1、MDM2及P53表达与GIST预后有关,三者对评价GIST预后是非常有意义的标记物。
Objective To investigate the expression of E2F1, MDM2 and P53 in gastrointestinal stromal tumors (GISTs) and their relationship with the clinicopathological characteristics and prognosis of GIST. Methods The expression of E2F1, MDM2 and P53 in 123 cases of GIST was detected by tissue microarray and immunohistochemical EnVision method. The relationship between the three expressions and the clinicopathological features was analyzed. The relationship between them and the prognosis of GIST was statistically analyzed. Results Among the 123 cases of GIST, 108 cases were evaluated by three proteins. The positive rates of E2F1, MDM2 and P53 in 62 cases were 62.0%, 43.5% and 57.4% respectively. There was a significant positive correlation between the expression of NIH and the NIH grade (all P <0.001). There were significant differences in the occurrence of necrosis and metastasis between the three groups (all P <0.05) The GIST in gut was significantly higher than that in gut and gut (P <0.05), but there was no significant difference between gut and gut (P> 0.05). However, GIST was significantly different between different age groups and different cell types No statistical significance (all P> 0.05). Conclusion The expressions of E2F1, MDM2 and P53 are related to the prognosis of GIST. The three markers are very useful in evaluating the prognosis of GIST.